Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study

Cooperberg, 2005, The changing face of prostate cancer, J Clin Oncol, 23, 8146, 10.1200/JCO.2005.02.9751 Thompson, 2005, Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower, JAMA, 294, 66, 10.1001/jama.294.1.66 Schröder, 2008, Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics, Eur Urol, 53, 468, 10.1016/j.eururo.2007.10.047 Mettlin, 1993, Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers, CA Cancer J Clin, 43, 42, 10.3322/canjclin.43.1.42 Benson, 1992, Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer, J Urol, 147, 815, 10.1016/S0022-5347(17)37393-7 Oesterling, 1993, Serum Prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges, JAMA J Am Med Assoc, 270, 860, 10.1001/jama.1993.03510070082041 Catalona, 1994, Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves, J Urol, 152, 2031, 10.1016/S0022-5347(17)32299-1 Henderson, 1997, Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer, J Natl Cancer Inst, 89, 134, 10.1093/jnci/89.2.134 Tomlins, 2011, Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA, Sci Transl Med, 3, 10.1126/scitranslmed.3001970 Salami, 2013, Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer, Urol Oncol, 31, 566, 10.1016/j.urolonc.2011.04.001 Tomlins, 2016, Urine TMPRSS2:ERG Plus PCA3 for individualized prostate cancer risk assessment, Eur Urol, 70, 45, 10.1016/j.eururo.2015.04.039 Sanda, 2017, Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer, JAMA Oncol, 3, 1085, 10.1001/jamaoncol.2017.0177 Chute, 1993, The prevalence of prostatism: a population-based survey of urinary symptoms, J Urol, 150, 85, 10.1016/S0022-5347(17)35405-8 Groskopf, 2006, APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer, Clin Chem, 52, 1089, 10.1373/clinchem.2005.063289 Clinical Laboratory and Standards Institute, 2000 Horowitz, 2008, Reference intervals: practical aspects, EJIFCC, 19, 95 Dixon, 1953, Processing data for outliers, Biometrics, 9, 74, 10.2307/3001634 Reed, 1971, Influence of statistical method used on the resulting estimate of normal range, Clin Chem, 17, 275, 10.1093/clinchem/17.4.275 Draisma, 2003, Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, J Natl Cancer Inst, 95, 868, 10.1093/jnci/95.12.868 Heijnsdijk, 2012, Quality-of-life effects of prostate-specific antigen screening, N Engl J Med, 367, 595, 10.1056/NEJMoa1201637 Gann, 1995, A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer, JAMA, 273, 289, 10.1001/jama.1995.03520280035036 Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918 Tosoian, 2021, Use of the MyProstateScore (MPS) Test to rule out clinically-significant cancer: validation of a straightforward clinical testing approach, J Urol, 205, 732, 10.1097/JU.0000000000001430 Mohler Klatte, 2012, Age-specific PCA3 score reference values for diagnosis of prostate cancer, World J Urol, 30, 405, 10.1007/s00345-011-0749-1 Young, 2012, Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden, Am J Clin Pathol, 138, 685, 10.1309/AJCPU7PPWUPYG8OH Florkowski, 2008, Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests, Clin Biochem Rev, 29, S83 Leyten, 2014, Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer, Eur Urol, 65, 534, 10.1016/j.eururo.2012.11.014 Bianchi-Frias, 2010, The effects of aging on the molecular and cellular composition of the prostate microenvironment, PLoS One, 5, 10.1371/journal.pone.0012501 Morote, 2010, Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia, World J Urol, 28, 677, 10.1007/s00345-010-0580-0 Wang, 2009, Rational approach to implementation of prostate cancer antigen 3 into clinical care, Cancer, 115, 3879, 10.1002/cncr.24447 Wolters, 2010, False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up, Am J Surg Pathol, 34, 35, 10.1097/PAS.0b013e3181c3ece9